NO930059D0 - O-GLYCOSYLERT IFN-ALFA - Google Patents

O-GLYCOSYLERT IFN-ALFA

Info

Publication number
NO930059D0
NO930059D0 NO930059A NO930059A NO930059D0 NO 930059 D0 NO930059 D0 NO 930059D0 NO 930059 A NO930059 A NO 930059A NO 930059 A NO930059 A NO 930059A NO 930059 D0 NO930059 D0 NO 930059D0
Authority
NO
Norway
Prior art keywords
ifn
glycosylert
alfa
glycosylated
alpha
Prior art date
Application number
NO930059A
Other languages
Norwegian (no)
Other versions
NO930059L (en
Inventor
Guenther Adolf
Adolf Himmler
Horst Johann Ahorn
Inge Kalsner
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904021917 external-priority patent/DE4021917A1/en
Priority claimed from DE19904035877 external-priority patent/DE4035877A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO930059L publication Critical patent/NO930059L/en
Publication of NO930059D0 publication Critical patent/NO930059D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The objects of the invention are O-glycosylated IFN-alpha, a process for producing the same and the use of the O-glycosylated proteins as medicinal drugs.
NO930059A 1990-07-10 1993-01-08 O-GLYCOSYLERT IFN-ALFA NO930059D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19904021917 DE4021917A1 (en) 1990-07-10 1990-07-10 O-glycosylated alpha-interferon, used as medicament - isolated following secretion into conditioned medium of mammalian cells contg. a suitable expression plasmid
DE19904035877 DE4035877A1 (en) 1990-11-12 1990-11-12 O-glycosylated alpha interferon
PCT/EP1991/001266 WO1992001055A1 (en) 1990-07-10 1991-07-06 O-glycosylated ifn-alpha

Publications (2)

Publication Number Publication Date
NO930059L NO930059L (en) 1993-01-08
NO930059D0 true NO930059D0 (en) 1993-01-08

Family

ID=25894855

Family Applications (1)

Application Number Title Priority Date Filing Date
NO930059A NO930059D0 (en) 1990-07-10 1993-01-08 O-GLYCOSYLERT IFN-ALFA

Country Status (16)

Country Link
EP (1) EP0538300B1 (en)
JP (1) JPH06502987A (en)
KR (1) KR930701601A (en)
AT (1) ATE104348T1 (en)
AU (1) AU650893B2 (en)
CA (1) CA2084514A1 (en)
CZ (1) CZ386392A3 (en)
DE (1) DE59101397D1 (en)
DK (1) DK0538300T3 (en)
ES (1) ES2063515T3 (en)
FI (1) FI930058A0 (en)
HU (1) HUT65846A (en)
NO (1) NO930059D0 (en)
PL (1) PL297610A1 (en)
SK (1) SK386392A3 (en)
WO (1) WO1992001055A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541071A (en) * 1992-02-07 1996-07-30 New England Medical Center Hospitals, Inc. Assay for identifying antagonists of gastrin and CCK-B receptors
NZ245771A (en) * 1992-02-07 1994-08-26 New England Medical Center Inc Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists
EP0626448A3 (en) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon
AU713611B2 (en) 1994-10-28 1999-12-09 Delft Diagnostic Laboratory B.V. New polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
JP2003530838A (en) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド Albumin fusion protein
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2305311A3 (en) * 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
ES2420581T3 (en) 2003-03-14 2013-08-26 Biogenerix Gmbh Branched water soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5743368B2 (en) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AR078117A1 (en) 2006-06-20 2011-10-19 Protech Pharma S A A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR20100016160A (en) 2007-04-03 2010-02-12 바이오제너릭스 에이지 Methods of treatment using glycopegylated g-csf
MX2009013259A (en) 2007-06-12 2010-01-25 Novo Nordisk As Improved process for the production of nucleotide sugars.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
RU2610173C1 (en) * 2016-03-30 2017-02-08 Илья Александрович Марков Recombinant plasmid pfm-ifn-17 providing expression of interferon alpha-2b of human, recombinant plasmid pfm-ap, providing expression of enzyme methionine-aminopeptidase e coli, biplasmid strain escherichia coli fm-ifn-ap (pfm-ifn-17, pfm-ap) - producer (met-) of recombinant interferon alpha -2b of human

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
JPS58501543A (en) * 1981-08-14 1983-09-16 エイ／エス　アルフレツド　ベンツオン Improvements regarding human interferon protein and antibodies against human interferon protein
DE3306060A1 (en) * 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim NEW IMMUNGLOBULIN-PRODUCING HYBRID CELL LINES, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF
FR2560212B1 (en) * 1984-02-24 1989-12-29 Unicet MONOCLONAL ANTIBODIES AGAINST INTERFERON A2 AND HYBRIDOMAS PRODUCING SUCH ANTIBODIES

Also Published As

Publication number Publication date
HU9300036D0 (en) 1993-04-28
SK386392A3 (en) 1994-08-10
KR930701601A (en) 1993-06-12
WO1992001055A1 (en) 1992-01-23
CZ386392A3 (en) 1993-08-11
FI930058A (en) 1993-01-08
NO930059L (en) 1993-01-08
CA2084514A1 (en) 1992-01-11
EP0538300A1 (en) 1993-04-28
EP0538300B1 (en) 1994-04-13
ES2063515T3 (en) 1995-01-01
JPH06502987A (en) 1994-04-07
AU650893B2 (en) 1994-07-07
AU8208291A (en) 1992-02-04
DK0538300T3 (en) 1994-10-10
FI930058A0 (en) 1993-01-08
ATE104348T1 (en) 1994-04-15
HUT65846A (en) 1994-07-28
DE59101397D1 (en) 1994-05-19
PL297610A1 (en) 1992-07-13

Similar Documents

Publication Publication Date Title
DK0538300T3 (en) O-Glycosylated IFN-alpha
ID28003A (en) ADAMANTANA'S DEMONS
NO307968B1 (en) Pyrazolo- and pyrrolopyridines and pharmaceutical mixtures thereof
FI915826A (en) PHARMACEUTICAL AEMNEN.
ES2036737T3 (en) PROCEDURE FOR OBTAINING PHARMACEUTICAL MIXTURES.
IT9047580A0 (en) PROCEDURE FOR THE TREATMENT OF INORGANIC POWDERS.
ITRM920237A1 (en) IMPROVED USE OF BRONCODILATORY MEDICINAL PRODUCTS B2.
DE3882593T2 (en) Polypeptide and its production.
DK0540609T3 (en) Cephalosporins and homologs, preparations and pharmaceutical preparations
DE58908155D1 (en) ENDOPROTHESIS OF THE HIP JOINT.
NO912825L (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IM MUNOGENT PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
NO911429L (en) DRUG TREATMENT.
NO913360L (en) PROCEDURE FOR THE PREPARATION OF SYNTHESIC GAS.
IT8919652A0 (en) PROCEDURE FOR THE PREPARATION OF N SULFONILUREAS.
DE59107762D1 (en) Complexes containing S (+) - phenyl-alkanoic acids and alpha-hydroxy-alkanoic acids
NO891574D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL USES.
NO892716D0 (en) PROCEDURE FOR PRODUCING PROTEINS.
IT9048026A0 (en) PHARMACEUTICAL AND/OR COSMETIC PREPARATION.
FR2631230B1 (en) FOLDABLE BED, ESPECIALLY FOR MEDICAL APPLICATIONS
NO891941D0 (en) PROCEDURE FOR THE MANUFACTURE OF CYCLOAL CADIANS.
MX9203129A (en) BMP-5 PROTEINS.
SE9002274D0 (en) NOVEL 3,3'-DITHIOBIS (PROPIONIC ESTERS).
MX9203467A (en) DERIVATIVES OF PEPTIDES.
NO871013L (en) PHARMACEUTICAL ARTICLE AND PROCEDURE FOR PREPARING THEREOF.
ATE92106T1 (en) POLYPEPTIDE AND ITS PRODUCTION.